Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-based Tandem HDCT in High-risk Neuroblastoma
NCT02771743Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2015
- Primary completion
- Mar 2020
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin, doxorubicin, etoposide, cyclophosphamide, ifosfamide and 4 more in neuroblastoma, sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
cisplatindoxorubicinetoposidecyclophosphamideifosfamide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02771743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771743.